实时支付与跨境解决方案 预计到2027年，支付交易额将增加至 250万亿美元，因此降低风险可谓是重中之重。随着企业采用更快捷的 支付系统并拓展全球交易业务，它们必须应对这些创新举措所带来的日益增长的欺诈风险。 通过理解并识别欺诈的动态特性，企业能够更有效地保护自身免受潜在风险的侵害。就2025年而言，攻击 和风险相关的关键趋势正逐渐显现。 以下是您必须了解并在支付领域制定应对方案的几个关键趋势： 高级欺诈预防 向着账户或资金发起的攻击和企图在不断地变化。每一年，新的预防措施与解决方案不断涌现，而欺诈者也 会随之更新其作案手法。 欺诈并非一成不变，而是在技术进步与恶意行为者不断创新的推动下持续发展 。 随着组织部署更为复杂的安全解决方案，欺诈者也会同步开发新策略以绕过这些防御机制。这场持续的博弈 凸显了保持警惕、持续更新安全协议以及利用最新技术来预判并抵御新型威胁的重要性。 随着欺诈者运用的技术愈发复杂，企业需借助人工智能、大数据以及数字身份技术，构建全面且主动的欺诈 预防策略。2023年，商业电子邮件泄露（BEC）在美国被列为成本第二高的犯罪类型，报告损失金额高达 29亿美元。若将人工智能因素纳入考量，多数专 ...

Group 1 - The article highlights the rise of scams targeting the elderly and children, particularly in the context of the "silver economy" and the popularity of certain children's toys [2][3] - As of the end of 2024, China's elderly population aged 60 and above is expected to exceed 310 million, accounting for 22% of the total population, leading to increased health consumption demands [2] - The Guangdong Provincial Market Supervision Administration has reported 184 cases of false advertising related to elderly medicines and health products this year, indicating a significant issue in consumer protection [2] Group 2 - Popular children's toys, such as "real cooking" kitchen toys and water guns, often lack necessary safety certifications and pose multiple safety hazards, including burns and chemical exposure [3] - Manufacturers and sellers are evading regulations by labeling products as suitable for ages 14 and above, using misleading marketing tactics, and fabricating production addresses [3] - The Guangdong market supervision authorities are increasing inspections around schools and e-commerce platforms to ensure compliance and protect children from unsafe products [3]

巴黎检察官：调查重点在于接受超出限额的选举竞选贷款。候选人在竞选期间接受非法贷款，涉嫌加重 洗钱、欺诈、伪造及使用伪造文件的行为。调查涉及2022年总统选举、2022年立法选举及2024年欧洲议 会选举的资金问题。尚未对任何个人或法人实体提出指控。（此前法国国民联盟主席称总部被警方突 袭。） ...

Core Viewpoint - A class action securities lawsuit has been filed against 3D Systems Corporation, alleging securities fraud that negatively impacted investors between August 13, 2024, and May 12, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that 3D Systems Corporation understated the impact of weakened customer spending on its business while overstating its resilience in challenging industry conditions [2]. - It is also alleged that updated milestone criteria in the partnership with United Therapeutics Corporation would adversely affect the revenue from the Company's regenerative medicine program [2]. - As a result, the Company's public statements were deemed materially false and misleading throughout the relevant period [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 12, 2025, to request to be appointed as lead plaintiff in the case [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Red Cat Holdings, Inc. for alleged securities fraud affecting investors between March 18, 2022, and January 15, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the production capacity of the Salt Lake City Facility and the value of the U.S. Army's Short Range Reconnaissance Program of Record Tranche 2 contract, leading to materially false and misleading public statements [2]. - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Issues - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, but has faced challenges with its authorized treatment centers (ATCs) [3]. - The company claimed that its ATCs would drive demand for Amtagvi; however, there were long timelines for patient treatment initiation and ineffective patient identification, leading to high patient drop-offs [4]. Financial Performance - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward due to "recent launch dynamics" and high patient drop-off rates [5]. - Following the announcement, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

Group 1 - The core issue involves a class action lawsuit against Rocket Pharmaceuticals, alleging violations of the Securities Exchange Act of 1934 related to misleading statements about the safety and clinical trial protocol of its gene therapy product RP-A501 [1][4][5] - The lawsuit claims that Rocket Pharmaceuticals failed to disclose serious adverse events, including patient deaths, during a Phase 2 clinical trial for Danon disease, which led to a significant drop in the company's stock price following the FDA's clinical hold announcement [4][5] - Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, are eligible to seek appointment as lead plaintiff in the class action lawsuit [1][6] Group 2 - Rocket Pharmaceuticals is characterized as a late-stage biotechnology company focused on developing gene therapies for rare diseases [3] - The law firm Robbins Geller Rudman & Dowd LLP, known for its expertise in securities fraud litigation, is representing the investors in this class action case [7]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has launched a nationwide special action to combat fraud and illegal activities in the pharmaceutical sector, utilizing drug traceability codes as a key tool, and has announced eight typical cases of violations [1]. Group 1: Cases of Fraudulent Activities - A case in Lanzhou, Gansu Province, involved a pharmacy selling drugs that had already been reimbursed by another pharmacy, indicating illegal resale of Medicare drugs. A total of 1,124 boxes of drugs, including high-value cancer treatment medications, were seized [2]. - Other cases include nine pharmacies in Wuhan, Hubei Province, involved in the resale of Medicare drugs; a pharmacy in Changsha, Hunan Province, that forged prescriptions; and a pharmacy in Fuzhou, Jiangxi Province, that swapped and resold Medicare drugs [3]. - Additional violations include a clinic in Hefei, Anhui Province, purchasing drugs from online platforms illegally; a pharmacy in Yangquan, Shanxi Province, inducing false purchases; and a doctor in Xi'an, Shaanxi Province, who prescribed excessive medications [3]. Group 2: Regulatory Actions and Warnings - The NHSA has emphasized that selling returned drugs is illegal and that traceability codes serve as a unique "electronic ID" for each drug. All Medicare-designated medical institutions must procure drugs with these codes and settle payments via scanning [3]. - Medicare beneficiaries are advised to use the national Medicare app to scan the traceability codes on drug packages and report any suspicious repeated settlements of returned drugs to protect their legal rights [3].

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Diversified Holdings and Compass Group Diversified Holdings, LLC (NYSE: CODI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Compass you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/compass-diversified-holdings. Investors ...